AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers

Go to navigation
Go to content

Reference code :: wf5383
Published date :: 30 October 2008
Expired date :: 29 July 2035

AstraZeneca has delivered a robust set of results, and on the back of this, is raising financial guidance for the full year. Additionally good progress is being made on reshaping the cost base, including advancing innovation in research and development activities with greater productivity and efficiency.

Download the narrative and the figures.

Not signed in

Page tools

Share price

London: 26.95 GBP
New York: 44.82 USD
Stockholm: 310.10 SEK

At 21-Nov-2009 09:24 GMT

Detailed share price

Introduction to AstraZeneca

Our responsibility

We continue to communicate openly on a range of issues, including:

Contact us

Stay in touch

Subscribe via RSS

This website is intended for people seeking information on the AstraZeneca International business. If you are in the US you should visit AstraZeneca US.

We also have national business sites which can be found under our list of AstraZeneca websites.

We also have specific national and international websites designed for patients and healthcare professionals. If you have a question you can contact us.